Bin Liu

US Patent:

7279477, Oct 9, 2007

Filed:

Jan 22, 2002

Appl. No.:

10/466926

Inventors:

Thomas Arrhenius - Del Mar CA, US
Mi Chen - San Diego CA, US
Jie Fei Cheng - Carlsbad CA, US
Yujin Huang - San Diego CA, US
Alex Michael Nadzan - Encinitas CA, US
Sovouthy Tith - San Diego CA, US
David Mark Wallace - San Diego CA, US
Bin Liu - Los Angeles CA, US
Masahiro Nishimoto - Susono, JP
Gary D. Lopaschuk - Edmonton, CA
Jason R. Dyck - Sherwood Park, CA

Assignee:

Chugai Seiyaku Kabushiki Kaisha - Tokyo

International Classification:

A61K 31/5375
C07D 265/30

US Classification:

5142378, 544106, 544158, 544159, 544160, 5142312, 5142375, 548240, 5483001, 5483351, 5483561

Abstract:

The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.

US Patent:

7786145, Aug 31, 2010

Filed:

Jul 28, 2004

Appl. No.:

10/900706

Inventors:

Jie Fei Cheng - Carlsbad CA, US
Bin Liu - Los Angeles CA, US
Thomas Arrhenius - Del Mar CA, US
Mark E. Wilson - Ramona CA, US
Alex M. Nadzan - Encinitas CA, US
Gary D. Lopaschuk - Edmonton, CA
Jason R. Dyck - Sherwood Park, CA
Rossy Serafimov - Metz, FR

Assignee:

Chugai Seiyaku Kabushiki Kaisha - Tokyo

International Classification:

A61K 31/4406
A61K 31/428
A61K 31/4025
C07D 417/12
C07D 277/72
C07D 207/14

US Classification:

514338, 514367, 514422, 5462701, 548166, 548518

Abstract:

The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.

US Patent:

8293714, Oct 23, 2012

Filed:

Apr 29, 2009

Appl. No.:

12/432528

Inventors:

Venkata Ramana Doppalapudi - San Diego CA, US
Jing-Yu Lai - San Diego CA, US
Bin Liu - San Diego CA, US
Dingguo Liu - San Marcos CA, US
Joel Desharnais - La Mesa CA, US
Abhijit Suresh Bhat - Encinitas CA, US
Yanwen Fu - San Diego CA, US
Bryan Douglas Oates - Carlsbad CA, US
Gang Chen - San Diego CA, US
Curt William Bradshaw - San Diego CA, US

Assignee:

Covx Technology Ireland, Ltd. - Dun Laoighaire, County Dublin

International Classification:

A61K 38/16

US Classification:

514 213, 514 81, 530324

Abstract:

The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.

US Patent:

8503588, Aug 6, 2013

Filed:

Nov 3, 2009

Appl. No.:

12/611810

Inventors:

Wei Luo - Marlboro NJ, US
Karthik Rajagopalan - San Diego CA, US
Andrew du Preez - San Diego CA, US
Bin Liu - San Diego CA, US
Shuangquan Wang - Morganville NJ, US

Assignee:

Broadcom Corporation - Irvine CA

International Classification:

H04B 1/10
H04L 25/08

US Classification:

375346, 375350

Abstract:

Aspects of a method and system for compensation of interference cancellation delay are provided. In this regard, a wireless communication device may receive one or more signals and may be operable to select, whether dynamically or statically, a processing path for processing the one or more received signals. The selected processing path may comprise one of an interference cancellation processing path and a pass-through processing path. A delay introduced by the pass-through processing path may be approximately equal to a processing delay introduced by the interference cancellation processing path. The one or more received signals may comprise HSDPA signals. The selection of processing path may be based on a measure of interference present in the one or more received signals.

US Patent:

8509698, Aug 13, 2013

Filed:

Jun 25, 2012

Appl. No.:

13/532410

Inventors:

Mark Hahm - Hartland WI, US
Wei Luo - Marlboro NJ, US
Thirunathan Sutharsan - San Diego CA, US
Andrew du Preez - San Diego CA, US
Bin Liu - San Diego CA, US
Jun Wu - San Diego CA, US
Shuangquan Wang - Morganville NJ, US

Assignee:

Broadcom Corporation - Irvine CA

International Classification:

H04B 1/00

US Classification:

455 631, 4551141, 4551142

Abstract:

Aspects of a method and system for a programmable interference suppression module may include receiving a communication signal comprising one or more desired signal, and one or more undesired signals. The communication signal may be utilized to generate estimated channel state information. The estimated channel state information may be formatted for use in interference suppression. A reduced interference signal may be generated from a delayed version of said communications signal and the estimated channel state information, wherein the one or more undesired signals may be attenuated. The reduced interference signal may be formatted for post-processing. The desired signals may comprise WCDMA and/or HSDPA signals, and the undesired signals may be inter-cell and/or intra-cell interference. Further processing may comprise HSDPA processing and/or RAKE finger processing. The communication signal may be a Universal Mobile Telecommunication System (UMTS) compliant signal.

US Patent:

8565287, Oct 22, 2013

Filed:

Oct 8, 2009

Appl. No.:

12/575879

Inventors:

Mark Hahm - Hartland WI, US
Wei Luo - Marlboro NJ, US
Bin Liu - San Diego CA, US
Jun Wu - San Diego CA, US
Shuangquan Wang - Morganville NJ, US

Assignee:

Broadcom Corporation - Irvine CA

International Classification:

H04B 1/00

US Classification:

375148, 375130, 375140, 375144, 375147, 375316, 375346, 375348

Abstract:

A wireless system may receive a plurality of multipath signals from a plurality of transmitters and allocate per-cell modules for generating an interference suppressed signal from the multipath signals. Data symbols may be sequentially processed in the received multipath signals utilizing the per-cell modules and subtracting the processed symbols from a residual buffer storing the received multipath signals. Desired information received from one or more of the transmitters may be recovered utilizing the interference suppressed signal. Timing of the data symbols may be correlated utilizing a cell chip combiner. The data symbols may be descrambled utilizing conjugated scrambling codes associated with one of the plurality of transmitters. Orthogonal variable spreading factor (OVSF) codes may be generated utilizing a Walsh transform on the data symbols. Power levels of the OVSF codes may be estimated and estimated signals may be generated based on the OVSF codes and the estimated power levels.

US Patent:

8208856, Jun 26, 2012

Filed:

Jan 13, 2010

Appl. No.:

12/686623

Inventors:

Mark Hahm - Hartland WI, US
Wei Luo - Marlboro NJ, US
Thirunathan Sutharsan - San Diego CA, US
Andrew du Preez - San Diego CA, US
Bin Liu - San Diego CA, US
Jun Wu - San Diego CA, US
Shuangquan Wang - Maple Shade NJ, US

Assignee:

Broadcom Corporation - Irvine CA

International Classification:

H04B 1/00

US Classification:

455 631, 4551141, 4551142, 4552781, 375214

Abstract:

Aspects of a method and system for a programmable interference suppression module may include receiving a communication signal comprising one or more desired signal, and one or more undesired signals. The communication signal may be utilized to generate estimated channel state information. The estimated channel state information may be formatted for use in interference suppression. A reduced interference signal may be generated from a delayed version of said communications signal and the estimated channel state information, wherein the one or more undesired signals may be attenuated. The reduced interference signal may be formatted for post-processing. The desired signals may comprise WCDMA and/or HSDPA signals, and the undesired signals may be inter-cell and/or intra-cell interference. Further processing may comprise HSDPA processing and/or RAKE finger processing. The communication signal may be a Universal Mobile Telecommunication System (UMTS) compliant signal.

US Patent:

20080070869, Mar 20, 2008

Filed:

Sep 14, 2007

Appl. No.:

11/855984

Inventors:

Thomas Arrhenius - Del Mar CA, US
Mi Chen - San Diego CA, US
Jie Fei Cheng - Carlsbad CA, US
Yujin Huang - San Diego CA, US
Alex Nadzan - Encinitas CA, US
Sovouthy Tith - San Diego CA, US
David Wallace - San Diego CA, US
Bin Liu - San Diego CA, US
Masahiro Nishimoto - Shizuoka, JP
Gary Lopaschuk - Edmonton, CA
Jason Dyck - Sherwood Park, CA

Assignee:

CHUGAI SEIYAKU KABUSHIKI KAISHA - Tokyo

International Classification:

A61K 31/66
A61K 31/155
A61K 31/185
A61P 3/10
A61P 9/00
A61P 35/00
A61P 3/04
A61K 31/277

US Classification:

514114000, 514237800, 514378000, 514399000, 514406000, 514461000, 514520000, 514553000, 514634000, 514640000, 514675000

Abstract:

The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.